ESPEYB20 6. Adrenals Svetlana Lajic, George Paltoglou, Leif Karlsson, Evangelia Charmandari (1 abstracts)
1Department of Womens and Childrens Health, Pediatric Endocrinology Unit; Karolinska University Hospital/Karolinska Institutet, 171 76 Stockholm, Sweeden; 2Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, Aghia Sophia Childrens Hospital, Athens, 11527, Greece; 3Division of Endocrinology and Metabolism, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 11527, Greece.
*Equal author contribution.
Evangelia Charmandari, MD, MSc, PhD, MRCP(UK), CCST(UK), Professor of Pediatric and Adolescent Endocrinology, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, Aghia Sophia Childrens Hospital, Thivon and Papadiamantopoulou Street, Athens, 11527, Greece; Tel/Fax: +30-213-2013 384
For this years chapter on Adrenals, we have searched the PubMed for articles on adrenal or steroidogenesis published in English between June 1, 2022 and May 31, 2023. Our search yielded more than 6,000 citations. We have examined all citations individually and selected the following collection of basic research and clinical articles. Whenever possible, we have avoided topics that have been discussed in the Yearbook 2022, unless progress in the field has been incremental. Emerging themes for this years chapter include: i) Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation in mice; ii) Circadian regulation of hippocampal function is disrupted with corticosteroid treatment; iii) Leukocyte telomere length is reduced in children with Congenital Adrenal Hyperplasia; iv) Metabotypes of CAH determined by gas chromatography-mass spectrometry in spot urine; v) A polygenic risk score helps discriminate primary adrenal insufficiency of different etiologies; vi) Crinecerfont, a CRF1 Receptor Antagonist, lowers adrenal androgens in adolescents with Congenital Adrenal Hyperplasia.